• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.PAR-1 和凝血酶:将微环境与黑色素瘤转移联系起来的纽带。
Cancer Res. 2011 Nov 1;71(21):6561-6. doi: 10.1158/0008-5472.CAN-11-1432. Epub 2011 Oct 18.
2
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.凝血酶受体(PAR-1)在黑色素瘤转移中的新作用——一个可能的治疗靶点。
Oncotarget. 2011 Jan-Feb;2(1-2):8-17. doi: 10.18632/oncotarget.211.
3
Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen.结直肠癌的生长和扩散依赖于凝血酶、基质 PAR-1 和纤维蛋白原。
Cancer Res. 2015 Oct 1;75(19):4235-43. doi: 10.1158/0008-5472.CAN-15-0964. Epub 2015 Aug 3.
4
Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis.蛋白酶激活受体1(PAR-1)是凝血酶增强实验性肺转移所必需的且具有限速作用。
Blood. 1998 Nov 15;92(10):3694-700.
5
miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells.微小RNA-20b调节黑色素瘤细胞中蛋白酶激活受体-1(PAR-1)凝血酶受体的表达。
Pigment Cell Melanoma Res. 2014 May;27(3):431-41. doi: 10.1111/pcmr.12217. Epub 2014 Feb 6.
6
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.蛋白酶激活受体-1 抑制 Maspin 肿瘤抑制基因,决定黑色素瘤的转移表型。
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):626-31. doi: 10.1073/pnas.1006886108. Epub 2010 Dec 27.
7
Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1.激肽释放酶相关肽酶-4 通过蛋白酶激活受体-1 启动前列腺癌中的肿瘤-基质相互作用。
Int J Cancer. 2010 Feb 1;126(3):599-610. doi: 10.1002/ijc.24904.
8
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.通过全身递送脂质体包裹的蛋白酶激活受体-1小干扰RNA靶向黑色素瘤生长和转移
Cancer Res. 2008 Nov 1;68(21):9078-86. doi: 10.1158/0008-5472.CAN-08-2397.
9
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1.Flotillin-2的上调与黑色素瘤进展相关,并调节凝血酶受体蛋白酶激活受体1的表达。
Cancer Res. 2004 Oct 15;64(20):7361-9. doi: 10.1158/0008-5472.CAN-04-0823.
10
Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43.蛋白酶激活受体-1的过表达通过调节连接蛋白43促进黑色素瘤转移。
Cancer Res. 2009 Aug 15;69(16):6730-7. doi: 10.1158/0008-5472.CAN-09-0300.

引用本文的文献

1
Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer.蛋白酶激活受体F2R是卵巢癌患者新的诊断/预后及治疗应用的潜在靶点。
Int J Mol Sci. 2025 Sep 2;26(17):8529. doi: 10.3390/ijms26178529.
2
Low-magnitude high-frequency vibration reduces prostate cancer growth and extravasation .低强度高频振动可抑制前列腺癌生长及扩散。
Mechanobiol Med. 2024 Aug 26;2(4):100095. doi: 10.1016/j.mbm.2024.100095. eCollection 2024 Dec.
3
Epigenetic Biomarkers in Thrombophilia-Related Pregnancy Complications: Mechanisms, Diagnostic Potential, and Therapeutic Implications: A Narrative Review.血栓形成倾向相关妊娠并发症中的表观遗传生物标志物:机制、诊断潜力及治疗意义:一项叙述性综述
Int J Mol Sci. 2024 Dec 20;25(24):13634. doi: 10.3390/ijms252413634.
4
Inhibition of Cancer Cell Migration and Invasion In Vitro by Recombinant Tyrosine-Sulfated Haemathrin, A Thrombin Inhibitor.重组酪氨酸硫酸化血纤维蛋白溶酶原激活物抑制剂体外抑制肿瘤细胞迁移和侵袭。
Int J Mol Sci. 2024 Nov 4;25(21):11822. doi: 10.3390/ijms252111822.
5
Recombinant hirudin and PAR-1 regulate macrophage polarisation status in diffuse large B-cell lymphoma.重组水蛭素和 PAR-1 调节弥漫性大 B 细胞淋巴瘤中巨噬细胞的极化状态。
BMC Biotechnol. 2024 Aug 12;24(1):55. doi: 10.1186/s12896-024-00879-w.
6
Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy.凝血蛋白酶驱动的癌症免疫逃逸:癌症免疫治疗的潜在靶点
Cancers (Basel). 2024 Apr 19;16(8):1568. doi: 10.3390/cancers16081568.
7
Impaired activation of plasmacytoid dendritic cells toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift.黑色素瘤来源的免疫抑制性细胞因子和代谢漂移介导了浆细胞样树突状细胞 toll 样受体 7/9 和 STING 的激活受损。
Front Immunol. 2024 Jan 3;14:1227648. doi: 10.3389/fimmu.2023.1227648. eCollection 2023.
8
The Role of Tissue Factor In Signaling Pathways of Pathological Conditions and Angiogenesis.组织因子在病理状态和血管生成信号通路中的作用
Curr Mol Med. 2024;24(9):1135-1151. doi: 10.2174/0115665240258746230919165935.
9
Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer.嵌合抗原受体 T 细胞靶向蛋白酶激活受体 1 治疗胰腺癌的研究进展
BMC Med. 2023 Sep 4;21(1):338. doi: 10.1186/s12916-023-03053-9.
10
Liquid biopsies for cancer: From bench to clinic.癌症的液体活检:从实验室到临床
MedComm (2020). 2023 Jul 23;4(4):e329. doi: 10.1002/mco2.329. eCollection 2023 Aug.

本文引用的文献

1
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.凝血酶受体(PAR-1)在黑色素瘤转移中的新作用——一个可能的治疗靶点。
Oncotarget. 2011 Jan-Feb;2(1-2):8-17. doi: 10.18632/oncotarget.211.
2
Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.因子 VIIa 与内皮细胞蛋白 C 受体结合可激活蛋白酶激活受体-1,并介导细胞信号转导和屏障保护。
Blood. 2011 Mar 17;117(11):3199-208. doi: 10.1182/blood-2010-09-310706. Epub 2011 Jan 20.
3
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.蛋白酶激活受体-1 抑制 Maspin 肿瘤抑制基因,决定黑色素瘤的转移表型。
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):626-31. doi: 10.1073/pnas.1006886108. Epub 2010 Dec 27.
4
Inhibition of mutated, activated BRAF in metastatic melanoma.转移性黑色素瘤中突变激活 BRAF 的抑制。
N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011.
5
High prevalence and risk factors of thromboembolism in stage IV melanoma.IV 期黑色素瘤患者血栓栓塞症的高患病率及相关危险因素。
J Eur Acad Dermatol Venereol. 2011 Mar;25(3):340-4. doi: 10.1111/j.1468-3083.2010.03795.x.
6
Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.凝血酶受体拮抗剂——抗血小板药物 SCH 530348 的潜力。
Expert Opin Pharmacother. 2010 Apr;11(6):1015-22. doi: 10.1517/14656561003720471.
7
Thrombin's central role in angiogenesis and pathophysiological processes.凝血酶在血管生成和病理生理过程中的核心作用。
Eur Cytokine Netw. 2009 Dec;20(4):171-9. doi: 10.1684/ecn.2009.0166.
8
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.蛋白酶激活受体-1(PAR-1)促进人类黑色素瘤的运动性,并与它们的转移表型相关。
Clin Exp Metastasis. 2010;27(1):43-53. doi: 10.1007/s10585-009-9301-8. Epub 2009 Dec 20.
9
Thrombin-activated receptors: promising targets for cancer therapy?凝血酶激活受体:癌症治疗的有前途靶点?
Curr Med Chem. 2010;17(2):109-28. doi: 10.2174/092986710790112639.
10
A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis.基质金属蛋白酶-1/蛋白酶激活受体-1 信号轴促进黑色素瘤的侵袭和转移。
Oncogene. 2009 Dec 3;28(48):4237-48. doi: 10.1038/onc.2009.272. Epub 2009 Sep 7.

PAR-1 和凝血酶:将微环境与黑色素瘤转移联系起来的纽带。

PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.

机构信息

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Cancer Res. 2011 Nov 1;71(21):6561-6. doi: 10.1158/0008-5472.CAN-11-1432. Epub 2011 Oct 18.

DOI:10.1158/0008-5472.CAN-11-1432
PMID:22009534
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3206157/
Abstract

Progression of melanoma is dependent on cross-talk between tumor cells and the adjacent microenvironment. The thrombin receptor, protease-activated receptor-1 (PAR-1), plays a key role in exerting this function during melanoma progression. PAR-1 and its activating factors, which are expressed on tumor cells and the surrounding stroma, induce not only coagulation but also cell signaling, which promotes the metastatic phenotype. Several adhesion molecules, cytokines, growth factors, and proteases have recently been identified as downstream targets of PAR-1 and have been shown to modulate interactions between tumor cells and the microenvironment in the process of melanoma growth and metastasis. Inhibiting such interactions by targeting PAR-1 could potentially be a useful therapeutic modality for melanoma patients.

摘要

黑色素瘤的进展取决于肿瘤细胞与相邻微环境之间的串扰。凝血酶受体,蛋白酶激活受体-1(PAR-1),在黑色素瘤进展过程中发挥着关键作用。PAR-1 及其激活因子在肿瘤细胞及其周围基质上表达,不仅诱导凝血,还诱导细胞信号转导,促进转移表型。最近已经确定了几种粘附分子、细胞因子、生长因子和蛋白酶作为 PAR-1 的下游靶点,并已证明它们可以调节黑色素瘤生长和转移过程中肿瘤细胞与微环境之间的相互作用。通过靶向 PAR-1 抑制这些相互作用可能是黑色素瘤患者的一种有用的治疗方式。